Trials / Recruiting
RecruitingNCT06919081
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Phase II Study of the Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- University of Illinois at Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome | Eye Drops |
| OTHER | Vehicle Control | Eye Drops |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2026-03-15
- Completion
- 2026-06-15
- First posted
- 2025-04-09
- Last updated
- 2026-01-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06919081. Inclusion in this directory is not an endorsement.